Guidance, NICE advice and quality standards In development

Skip to filtersSkip to results

Skip to results

Expected publication date

Expected publication date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme 1 selected

Guidance programme

Showing 251 to 275 of 323

TitleTypeExpected publication date
Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive, HER2-negative early breast cancer [ID6153]Technology appraisal guidanceTBC
Risankizumab for previously treated moderately to severely active ulcerative colitis in people aged 16 and over ID6209Technology appraisal guidanceTBC
Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]Technology appraisal guidanceTBC
Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]Technology appraisal guidanceTBC
Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly [ID1596]Technology appraisal guidanceTBC
Rozanolixizumab for treating antibody-positive generalised myasthenia gravis [ID5092]Technology appraisal guidanceTBC
Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy [ID5100]Technology appraisal guidance
Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (Review of TA611) [ID4069]Technology appraisal guidance
Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids in people aged 12 and over [ID6377]Technology appraisal guidance
Ruxolitinib for treating moderate to severe chronic graft-versus-host disease after an allogeneic stem cell transplant in people 28 days to 17 years [ID6427]Technology appraisal guidanceTBC
Ruxolitinib for treating non-segmental vitiligo in people 12 years and over [ID3998]Technology appraisal guidance
Sacituzumab govitecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor [ID6375]Technology appraisal guidanceTBC
Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more therapies [ID4033]Technology appraisal guidanceTBC
Sacituzumab govitecan for treating unresectable metastatic urothelial cancer [ID6150]Technology appraisal guidanceTBC
Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over ID6284Technology appraisal guidanceTBC
Secukinumab for treating enthesitis-related arthritis or juvenile psoriatic arthritis [ID3738]Technology appraisal guidanceTBC
Selpercatinib for advanced thyroid cancer with RET alterations that has not been treated with systemic therapy [ID6132]Technology appraisal guidance
Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (MA review of TA760) [ID6293]Technology appraisal guidance
Selpercatinib for treating RET fusion-positive advanced solid tumours in people aged 12 and over with no other treatment options [ID6273]Technology appraisal guidanceTBC
Selpercatinib for untreated RET-positive advanced thyroid cancer [ID6183]Technology appraisal guidanceTBC
Semaglutide for preventing major cardiovascular events in people with cardiovascular disease and living with overweight or obesity ID6441Technology appraisal guidanceTBC
Sipavibart for preventing COVID 19 [ID6282]Technology appraisal guidanceTBC
Sirolimus for treating facial angiofibroma from tuberous sclerosis complex in people 6 years and older [ID6440]Technology appraisal guidanceTBC
Sodium phenylbutyrate–ursodoxicoltaurine for treating amyotrophic lateral sclerosis [ID6246]Technology appraisal guidanceTBC
Somapacitan for treating growth hormone deficiency in children [ID6178]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All